PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

Pharmacogenomics holds promise for personalized dementia therapies

Pharmacogenomics-based studies in the research for personalized therapeutics for dementia

November 8, 2023

ATMA Welcomes Dr. Scott Shannon, MAPS MDMA Phase 3 Principal Investigator, to Expand Its’ Clinical Training Expertise in MDMA-Assisted Therapy | Psychedelic Invest

Dr. Shannon will provide valuable expertise towards MDMA-Assisted Therapy Training from a MAPS clinical protocols foundation. ATMA Journey Centers Inc. (“ATMA”), a Canadian company with

October 25, 2023

Late-stage results set up Cytokinetics heart drug to compete with Bristol

Late-stage results of Cytokinetics’ drug for a rare heart disease suggest it can compete with a similar treatment sold by Bristol Myers Squibb on efficacy

May 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.